San Francisco Bay Area biotech stories.
Tuesday, May 1, 2012
Gilead strikes deal with antibody drug technology company AnaptysBio
Gilead Sciences Inc. will use technology from AnaptysBio Inc. to develop new antibody drug leads
. Gilead (NASDAQ: GILD) made an upfront payment, according to AnaptysBio, a privately held company in San Diego, and will provide research funding to AnaptysBio. Specific figures were not disclosed by AnaptysBio, and the company didn’t say which disease areas Foster City-based Gilead would target with the technology.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)